Totschnig, D.; Augustin, M.; Niculescu, I.; Laferl, H.; Jansen-Skoupy, S.; Lehmann, C.; Wenisch, C.; Zoufaly, A.
SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience. Viruses 2022, 14, 2278.
https://doi.org/10.3390/v14102278
AMA Style
Totschnig D, Augustin M, Niculescu I, Laferl H, Jansen-Skoupy S, Lehmann C, Wenisch C, Zoufaly A.
SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience. Viruses. 2022; 14(10):2278.
https://doi.org/10.3390/v14102278
Chicago/Turabian Style
Totschnig, David, Max Augustin, Iulia Niculescu, Hermann Laferl, Sonja Jansen-Skoupy, Clara Lehmann, Christoph Wenisch, and Alexander Zoufaly.
2022. "SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience" Viruses 14, no. 10: 2278.
https://doi.org/10.3390/v14102278
APA Style
Totschnig, D., Augustin, M., Niculescu, I., Laferl, H., Jansen-Skoupy, S., Lehmann, C., Wenisch, C., & Zoufaly, A.
(2022). SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience. Viruses, 14(10), 2278.
https://doi.org/10.3390/v14102278